Bionano Genomics, Inc.
BNGO
$1.18
-$0.02-1.67%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 30.18M | 28.74M | 28.51M | 28.72M | 27.43M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 30.18M | 28.74M | 28.51M | 28.72M | 27.43M |
| Cost of Revenue | 15.84M | 15.24M | 15.32M | 15.52M | 26.04M |
| Gross Profit | 14.34M | 13.50M | 13.18M | 13.20M | 1.39M |
| SG&A Expenses | 34.32M | 34.13M | 35.15M | 38.19M | 38.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.37M | 61.51M | 61.85M | 65.33M | 78.12M |
| Operating Income | -32.19M | -32.77M | -33.34M | -36.61M | -50.70M |
| Income Before Tax | -32.10M | -31.53M | -26.33M | -38.56M | -74.29M |
| Income Tax Expenses | 66.00K | 69.00K | 66.00K | 32.00K | 42.00K |
| Earnings from Continuing Operations | -32.16 | -31.60 | -26.40 | -38.59 | -74.33 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -32.16M | -31.60M | -26.40M | -38.59M | -74.33M |
| EBIT | -32.19M | -32.77M | -33.34M | -36.61M | -50.70M |
| EBITDA | -22.87M | -23.37M | -23.81M | -27.02M | -37.85M |
| EPS Basic | -3.76 | -5.11 | -5.51 | -16.96 | -46.29 |
| Normalized Basic EPS | -2.35 | -3.19 | -3.44 | -7.76 | -16.79 |
| EPS Diluted | -3.76 | -5.11 | -5.51 | -16.96 | -46.29 |
| Normalized Diluted EPS | -2.35 | -3.19 | -3.44 | -7.76 | -16.79 |
| Average Basic Shares Outstanding | 38.16M | 30.05M | 21.77M | 13.12M | 9.21M |
| Average Diluted Shares Outstanding | 38.16M | 30.05M | 21.77M | 13.12M | 9.21M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |